1686 results about "Moiety" patented technology

The present disclosure relates to compositions and methods for reversible fixation of biological samples using fixation reagents that form bis-carbamate crosslinks between amine-bearing moieties in biomolecules.

A multifunctional organosilicon compound is provided which has the general formula XSi([OSiR2]p-0-SiR2Y)a(R1)3-a— ln the formula, X is selected from H and ethylenically un saturated moieties; each Y independently comprises a functional moiety selected from alkoxysilyl moieties, acryloxy moieties, and epoxide moieties; each R is an independently selected hydrocarbyl group; each R1 is an independently selected hydrocarbyl group; subscript a is 1, 2, or 3; and each subscript b is independently 0, 1, or 2. A method of preparing the multifunctional organosilicon compound is also provided. The method comprises reacting (A) an organosilanol compound and (B) a silane compound having at least two hydrolysable groups. A functionalized siloxane compound prepared from the multifunctional organosilicon compound, a method of preparing the functionalized siloxane compound, and an adhesive comprising the functionalized siloxane compound are also provided.

The present disclosure relates in some aspects to methods, systems, and kits for sequencing a template nucleic acid molecule, where the methods comprise: (i) contacting a priming strand bound to the template nucleic acid molecule with a first plurality of nucleotide molecules and a polymerase coupled to a heterologous polynucleotide-binding moiety to form a complex comprising a 3′ terminus of the priming strand, the template nucleic acid molecule, the polymerase, and a nucleotide molecule of the first plurality of nucleotide molecules, wherein the polynucleotide-binding moiety enhances stability of the complex, and wherein the priming strand comprises a reversibly-terminated nucleotide at its 3′ end such that the nucleotide molecule of the transient complex is not incorporated; and (ii) detecting a presence of the nucleotide molecule in the complex to identify a complementary nucleotide in the template nucleic acid molecule.

A method of preparing an acrylate-functional branched organosilicon compound (“compound”) is provided, and comprises reacting (A) a branched organosilicon compound and (B) an acrylate compound in the presence of (C) a catalyst, wherein component (A) has the general formula X—Si(R1)3, where X comprises a halogen-functional moiety and each R1 is selected from R and —OSi(R4)3, with the proviso that at least one R1 is —OSi(R4)3; each R4 is selected from R, —OSi(R5)3, and —[OSiR2]mOSiR3; each R5 is selected from R, —OSi(R6)3, and —[OSiR2]mOSiR3; each R6 is selected from R and —[OSiR2]mOSiR3; each R is an independently selected hydrocarbyl group; and 0≤m≤100; with the proviso that at least one of R4, R5 and R6 is —[OSiR2]mOSiR3. The compound prepared by the method, a copolymer comprising the reaction product of the compound and a second compound, a method of forming the copolymer, and a composition comprising the copolymer are each also provided.

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.

The present disclosure is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In certain embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcγRI, FcRN, Transferrin or Macrophage Scavenger receptor.

Linkers for linking a therapeutic agent to other moieties, such as an Fc region of an antibody. A linker having two or more maleimide functional groups, which may be subjected to a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by linking a novel linker to the Fc region of an antibody. Antibody drug conjugates having a longer duration of action than the drug alone.

The present disclose provides a method for classifying a sample derived from a subject. The method may comprise obtaining a sample comprising nucleic acid molecules from the subject. The method can comprise assaying the nucleic acid molecules to generate a data set comprising methylation states of one or more genomic regions. The one or more genomic regions can comprise differentially methylation regions (DMRs). The method can comprise processing at least a portion of the data set to generate an output indicative of cancer in the subject. The portion of the data set can pertain to a set of DMRs specific to the subject.

A system and method for modeling one or more characteristics of a molecule using a quantum device implemented on quantum hardware is disclosed. Through control, via modulation, of coupling strengths between qubits on the quantum device and a comparison to an experimentally-measured nuclear magnetic resonance spectrum, J-coupling values may be deduced. These J-coupling values may then be used to recover the molecular structure of the given molecule. The control of coupling strengths may take place through an iterative process until convergence to the one or more characteristics is reached. In some embodiments, such a process may be implemented as part of a quantum computing service. In such cases, the quantum hardware may be local to the quantum computing service, or may be outsourced to a quantum hardware provider.

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

Disclosed are microcapsule compositions having a microcapsule that contains a microcapsule core and a microcapsule shell encapsulating the microcapsule core. The microcapsule has a particle size of 1 micron to 100 microns in diameter. The microcapsule core contains an active material. The microcapsule shell is formed of at least three moieties, in which a first moiety is derived from a polygalactomannan, a second moiety is derived from a polyisocyanate, and a third moiety is derived from a multi-functional aldehyde or a tannic acid.

Provided herein are methods, compositions, and kits for detecting analytes of interest from biological samples using tagmentation. The method comprises: (a) hybridising a nucleic acid analyte to a capture probe on an array, wherein the capture probe comprises: (i) a spatial barcode and (ii) a capture domain; (b) extending the capture probe using the nucleic acid analyte as a template, thereby generating a barcoded nucleic acid molecule on the array, wherein the barcoded nucleic acid molecule comprises a complement of the sequence of the nucleic acid analyte; and (c) tagmenting the barcoded nucleic acid molecule or a derivative thereof using a transposome comprising a transposase to insert a transposon end sequence into the barcoded nucleic acid molecule or the derivative thereof, thereby generating a barcoded nucleic acid fragment, wherein the barcoded nucleic acid fragment comprises: (i) the barcode, (ii) the transposon end sequence, and (iii) at least a portion of a sequence of the nucleic acid analyte or a complement thereof.

In some aspects, the present disclosure provides systems for forming hydrogels that comprise (i) a reactive multi-arm polymer that comprises three or more polymer arms linked to a core region, each arm comprising a polyether segment and a reactive moiety comprising a cyclic imide carboxy-C1-C5-alkyl ester end group or each arm comprising a polyether segment and a reactive moiety comprising a C2-C6-isocyanoalkyl end group and (ii) a polyamino compound comprising at least two amino (-NH2) groups, wherein the reactive multi-arm polymer and the polyamino compound react to form a crosslinked hydrogel that does not contain ester groups and has long-term stability in vivo. In some aspects, the present disclosure provides methods of treatment using such systems and hydrolysis-resistant crosslinked hydrogels formed from such systems.

A compound of Formula Ir(LA)x(LB)y(LC)z is provided where x and y are independently 1 or 2; z is 0 or 1; and x+y+z=3; first ligand LA includes a structure of Formula I,ligand LB includes a structure of Formula II:and ligand LC is a bidentate ligand. In the compounds, moiety B is a polycyclic fused ring system comprising at least four rings; each of moiety C and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z6 is C or N; L0 is a direct bond or a linking group; YA is a linking group; each substituent is hydrogen or a General Substituent defined herein; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

The present disclosure relates to targeting moieties such as peptides that can bind to B7-H3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention discloses a self-assembly-based DNA molecular weight standard preparation method, which comprises: S1, chemically synthesizing two single-stranded DNAs having the same length but not completely complementary, and each of the two single-stranded DNAs is composed of two parts of sequences: one part is a complementary sequence, and the other part is a self-assembly complementary sequence; s2, mixing in a reaction buffer solution for directional self-assembly, and adding ligase; s3, reacting at room temperature for 0.5-10 minutes, regulating and controlling the number of self-assembly times by controlling the reaction time, and increasing the base number equal to the base number of the single-stranded DNA in each connection to form a plurality of DNA molecular weight standards with sequence lengths gradually increased in an equal difference manner; s4, carrying out thermal inactivation treatment; and S5, adding an electrophoresis loading buffer solution to prepare a DNA molecular weight standard, and storing at low temperature. The DNA molecular weight standard is rapidly prepared through the one-pot method, and the method has the advantages of being simple in process, low in manufacturing cost, high in expansibility and the like and has good application prospects.

A computer-implemented method is provided for monitoring and / or controlling a chemical and / or biological process. The method comprises: obtaining (S10) a time series dataset comprising observations, each one of the observations being collected with respect to the chemical and / or biological process at a particular time point, wherein each one of the observations includes values of observed parameters obtained with a spectroscopic method at the particular time point and a value of an analyte parameter obtained with a reference measurement method at the particular time point; obtaining (S20) a prediction model for estimating a predicted value of the analyte parameter in the chemical and / or biological process, the prediction model being trained using at least part of the time series dataset; validating (S30) the prediction model by assessing an ability of the prediction model to predict a difference between an actual value of the analyte parameter which would be obtained with the reference measurement method at a given time point and an expected value of the analyte parameter at the given time point, using a set of observations that is not included in the at least part of the time series dataset used for training the prediction model; determining (S40) whether the prediction model is valid or invalid based on a result of the validating; and monitoring and / or controlling (S50) the chemical and / or biological process when the prediction model is determined to be valid.

The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.

Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.

The invention relates to organic electroluminescent materials and devices. There is provided a compound having the formula Ir (LA) x (LB) y (LC) z wherein x and y are each independently 1 or 2, z is 0 or 1, and x + y + z = 3; the first ligand LA comprises a structure as shown in a formula I; lB comprises a structure of formula II; and LC is a bidentate ligand. In these structures, each of the moieties A, C and D is a monocyclic or polycyclic fused ring system; each of X1-X7 and Z1-Z4 is C or N; y1 is a linking group; z is Si or Ge; and each substituent is hydrogen or a universal substituent as defined herein. Formulations, OLEDs, and consumer products containing the compounds are also provided. Further provided is a method of preparing a compound of formula M '(LA') p (LB ') q (LC') r as defined herein.

The present invention relates to a novel compound selected from a protein degrader or conjugate including a PI3K target moiety and an HSP90 target moiety linked through a linker, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The compound can treat cancer through a degradation pathway of a heat shock protein conjugate.

In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a radiopaque polyamino compound and (b) a reactive polymer comprising a plurality of hydrophilic polymer segments and a plurality of reactive moieties, wherein the reactive moieties are reactive with amino groups of the radiopaque polyamino compound, and wherein the radiopaque polyamino compound is produced by a method that comprises: (i) converting hydroxyl groups of a polyhydroxylated radiopaque compound to amino groups, (ii) converting vicinal diol groups (—CHOHCH2OH groups) of a polyhydroxylated radiopaque compound into hydroxyaminoethyl groups (—CHOHCH2NH2 groups), or (iii) converting vicinal diol groups of a polyhydroxylated radiopaque compound into aminomethyl groups (—CH2NH2 groups). In other aspects, the present disclosure pertains to hydrogels formed from such systems and to methods of treatment using such systems.

Provided herein are methods and systems for sequencing proteins. One or more methods disclosed herein may use linkers having an amino acid-reactive group and an additional reactive moiety that may be used to couple a polymerizable molecule. The linker may couple to a polymerizable molecule and an amino acid of a peptide and a capture moiety via the polymerizable molecule, followed by cleavage of the amino acid from the peptide. Further processing and analysis may be conducted using, for example, nanopores or nanogaps.

The invention features compounds containing an aziridine moiety and methods of synthesizing the same. The compounds may be bound to a monovalent organic moiety and may be used to bind to a target (e.g., a target protein), for example, by cross-linking the target. In some embodiments, the monovalent organic moiety is capable of binding to a presenter protein. Also disclosed are complexes containing the compounds (e.g., presenter protein / compound complexes, compound / target protein complexes, or tri-complexes). Methods of forming the complexes and methods of using the compounds and complexes to modulate biological processes are also disclosed.

Organotin compositions having the formula RSnL3 and corresponding synthetic methods are described. R includes aromatic, cyclic and / or halogenated ether moieties, or polyethers, and L includes hydrolysable groups. The organotin compositions may be formed as radiation-patternable coatings on substrates. The coatings may have an average thickness from about 1 nm to about 75 nm and have the formula RSnOn(OH)3-2n, forming an oxo-hydroxo network, where R is a hydrocarbyl ether group with 1 to 30 carbon atoms and 0<n<3 / 2, wherein regions of the coating are soluble in 2-heptanone in a puddle development step following a bake at 150° C. for 120 seconds. The coatings may be radiation-patternable using UV, EUV or ion beam radiation, and corresponding methods are described.

The present disclosure relates to the synthesis of cyclic peptides that are able to effectively deliver cargo, e.g., a therapeutic moiety (TM), inside a cell to treat a variety of conditions and diseases.

The purpose of the present invention is to provide a bismaleimide compound which has good compatibility with other resins, has a high Tg value and can be developed by an alkali. This bismaleimide compound is represented by general formula (1). In formula (1), X moieties are each independently a divalent hydrocarbon group having 6-200 carbon atoms, Y moieties are each independently a divalent hydrocarbon group having 6-50 carbon atoms, and Z moieties are each independently a hydrogen atom or a monovalent group that is a carboxyl group-containing organic group or an ethylenically unsaturated group-containing organic group. However, at least one Z moiety is a carboxyl group-containing organic group or an ethylenically unsaturated group-containing organic group. n is the average number of repeating units, and represents an integer between 1 and 100.

Disclosed are cell-penetrating cyclic peptides. The peptides can be used to deliver peptides and other biologically active moieties into cells. Formulations containing the cell-penetrating cyclic peptides are also described.

The present disclosure provides a compound comprising a radiolabeling moiety, a targeting moiety, and a DNA intercalating agent and complexes thereof For example, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt and / or solvate thereof. Methods of making and uses thereof, such as cancer theranostic applications, are also included. (I)